Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research
Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website ( ptglab.com). The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their work, from basic research to the design of novel therapeutics.
This press release features multimedia. View the full release here:
On the Proteintech website (ptglab.com), researchers can explore antibody binding sites with the new interactive 3D epitope viewer. (Photo: Business Wire)
The 3D Epitope Mapping is a state-of-the-art solution that utilizes a combination of experimental techniques, including peptide scanning and microbial display, aiming to precisely map the antibody binding site (epitope) on a target protein. This mapping is then visualized in an interactive 3D view, which is based on published protein data and AI modelling. The 3D visualization provides scientists with a clear and detailed representation of the antibody-binding sites, enabling improved speed and precision of their antibody selection.
In addition to the 3D Epitope Mapping, Proteintech improved the display of its immunogen information. The immunogen data is now displayed as a bar graph at the top of the search return pages, allowing users to select antibodies based on their immunogen of interest.
'We are thrilled to be the first antibody supplier to offer advanced product information that we believe will make a significant impact on the life science community. As the original manufacturer of these products, we believe we are uniquely positioned to be able to provide this data to scientists. We plan to have our entire catalog mapped in the near future,' said Dr. Jason Li, CEO at Proteintech. 'With more epitopes mapped, we hope the days when scientists have to try multiple antibodies for one experiment are behind us. Scientists deserve better when they are fighting for the future of mankind.'
Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering two-thirds of the human proteome. Proteintech offers antibodies, proteins and immunoassays across research areas with over 300,000 products cited. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited.
ph: 312-455-8498
INDUSTRY KEYWORD: MEDICAL SUPPLIES BIOTECHNOLOGY MANAGED CARE HEALTH PHARMACEUTICAL HEALTH TECHNOLOGY OTHER SCIENCE RESEARCH HOSPITALS GENETICS SCIENCE
SOURCE: Proteintech Group Inc.
Copyright Business Wire 2025.
PUB: 03/07/2025 02:16 PM/DISC: 03/07/2025 02:17 PM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 hours ago
- Business Wire
2025 Zhejiang (Egypt) International Engineering Exhibition Successfully Held
RIYADH, Saudi Arabia & CAIRO--(BUSINESS WIRE)--From June 17th to 19th, 2025, the Zhejiang (Egypt) International Engineering Exhibition was successfully held in Hall 3 of the Cairo International Exhibition Center. Hosted by the Department of Commerce of Zhejiang Province and organized by the Zhejiang International Contractors Association and Hangzhou Boheng Business Exhibition Co., Ltd., the exhibition was held alongside the prominent 2025 Egypt Big 5 Construction Show. Zhejiang showcased its unified provincial image through a dedicated area featuring 10 enterprises, 15 representatives, and an exhibition space of 108 square meters. Participating companies included Yoking Pump Co., Ltd., Zhitao Electric Group Co., Ltd., Zhejiang Qiankai Electric Equipment Co., Ltd., and Hangzhou Fulltime Robotics Co., Ltd. Over three days, Zhejiang enterprises interacted with more than 920 professional merchants from 12 countries and regions, resulting in intended transaction amounts of $5.7 million. Strategically located at the crossroads of Asia, Africa, and Europe, Egypt plays a key role in the Belt and Road Initiative. In May 2024, China and Egypt signed the Cooperation Plan on Jointly Promoting the Construction of the Belt and Road Initiative, which defined key cooperation areas. This strengthened framework will deepen collaboration and fuel development. To diversify its economy, Egypt has initiated projects like 'Egypt Vision 2030,' the New Administrative Capital, and the Suez Canal Corridor—sectors with strong demand for construction and renewable energy. These developments open new avenues for Zhejiang enterprises to participate in Egypt's infrastructure upgrades. Zhejiang Province has been advancing its 'Sweet Potato Economy' strategy to upgrade the 'No. 1 Opening-Up Project.' In 2024, newly signed foreign contracting projects totaled $5.486 billion (up 11.57%), with a completed turnover of $7.995 billion (up 15.27%), ranking fourth nationwide in business scale. This Egyptian exhibition marked Zhejiang's first self-organized overseas event in 2025. Themed 'Shaping a Smart, Green Future with Zhejiang,' it underscored the province's capabilities in green technology and smart construction. Zhejiang will continue to leverage overseas exhibitions to help more enterprises expand globally, foster cooperation and technology exchange, and offer sustainable solutions to global engineering challenges.
Business Wire
13 hours ago
- Business Wire
U-Haul Offers Disaster Relief After Derecho Hits North Dakota, Minnesota
FARGO, N.D.--(BUSINESS WIRE)--U-Haul ® is extending 30 days of free self-storage and U-Box ® container usage at seven centers across eastern North Dakota and northern Minnesota to residents affected by tornadoes that left a wide path of destruction Friday night and into the early hours of Saturday. U-Haul is extending 30 days of free self-storage and U-Box container usage at seven centers in North Dakota and Minnesota to residents impacted by the derecho. Share A derecho with winds exceeding 100 mph moved across numerous counties in both states, damaging properties and leaving thousands without power. There were multiple tornado sightings throughout the fast-moving storm system. Enderlin, N.D., located southwest of Fargo, and Bemidji, Minn., were among the communities hardest hit. Access to dry and secure self-storage and portable storage containers can be vital to communities during the clean-up and recovery process after natural disasters. The 30 days free offer applies to new self-storage and U-Box rentals and is based on availability. The U-Box offer is for on-site storage at Company centers, and for customers who tow their portable storage container. U-Box delivery and pick-up is also available for a modest cost. People seeking more information on the disaster relief program or needing to arrange storage services can contact the nearest participating U-Haul facility: NORTH DAKOTA U-Haul Moving & Storage of 13th Ave. 4901 13th Ave S. Fargo, ND 58103 (701) 205-3260 U-Haul Moving & Storage of Fargo 1436 Main Ave. Fargo, ND 58103 (701) 293-5256 U-Haul Moving & Storage of Osgood 5200 Veterans Blvd. Fargo, ND 58104 (701) 492-8900 U-Haul Storage of Fargo 610 42nd St. N. Fargo, ND 58102 (701) 639-7714 MINNESOTA U-Haul Moving & Storage of Moorhead 50 County Road 9 Dilworth, MN 56529 (218) 303-1480 U-Haul Storage of Nisswa 4745 County Road 77 Nisswa, MN 56468 (218) 963-5106 U-Haul Storage North Baxter 15237 Edgewood Dr. Brainerd, MN 56401 (218) 297-3018 In addition to its 30 days free self-storage disaster relief program, U-Haul is proud to be at the forefront of aiding communities in times of need as an official American Red Cross Disaster Responder. About U-HAUL Celebrating our 80th anniversary in 2025, U-Haul is the No. 1 choice of do-it-yourself movers with more than 24,000 rental locations across all 50 states and 10 Canadian provinces. The U-Haul app makes it easy for customers to use U-Haul Truck Share 24/7 to access trucks anytime through the self-dispatch and -return options on their smartphones with our patented Live Verify technology. Our customers' patronage has enabled the U-Haul fleet to grow to 193,900 trucks, 138,200 trailers and 40,300 towing devices. U-Haul is the third largest self-storage operator in North America and offers 1,060,000 rentable storage units and 92.0 million square feet of self-storage space at owned and managed facilities. U-Haul is the top retailer of propane in the U.S. and the largest installer of permanent trailer hitches in the automotive aftermarket industry. Get the U-Haul app from the App Store or Google Play.
Business Wire
a day ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
